Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

China Health Group Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

China Health Group şirketinin toplam hissedar öz sermayesi HK$59.8M ve toplam borcu HK$5.5M olup, bu da borç-öz sermaye oranını 9.2% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla HK$192.3M ve HK$132.6M dir.

Anahtar bilgiler

9.2%

Borç/özkaynak oranı

HK$5.51m

Borç

Faiz karşılama oranı	n/a
Nakit	HK$8.98m
Eşitlik	HK$59.75m
Toplam yükümlülükler	HK$132.56m
Toplam varlıklar	HK$192.32m

Son finansal sağlık güncellemeleri

We Think China Health Group (HKG:673) Has A Fair Chunk Of Debt

Dec 01

Recent updates

Here's Why China Health Group Limited's (HKG:673) CEO Compensation Is The Least Of Shareholders' Concerns

Sep 05

Shareholders Will Probably Not Have Any Issues With China Health Group Limited's (HKG:673) CEO Compensation

Sep 11

We Think China Health Group (HKG:673) Has A Fair Chunk Of Debt

Dec 01

We Discuss Why China Health Group Limited's (HKG:673) CEO May Deserve A Higher Pay Packet

Sep 23

We Think Some Shareholders May Hesitate To Increase China Health Group Limited's (HKG:673) CEO Compensation

Sep 02

Did China Health Group Limited (HKG:673) Insiders Sell Shares?

Feb 16

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 673 'nin kısa vadeli varlıkları ( HK$129.0M ) kısa vadeli yükümlülüklerini ( HK$112.1M ) aşıyor.

Uzun Vadeli Yükümlülükler: 673 şirketinin kısa vadeli varlıkları ( HK$129.0M ) uzun vadeli yükümlülüklerini ( HK$20.5M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 673 şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: 673 şirketinin borç/öz sermaye oranı son 5 yılda 0% seviyesinden 9.2% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: 673 şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: 673 serbest nakit akışı tahminlerine göre 9 ay boyunca yeterli nakit akışına sahip olması öngörülüyor, ancak o zamandan beri ek sermaye artırdı.

China Health Group Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

We Think China Health Group (HKG:673) Has A Fair Chunk Of Debt

Recent updates

New minor risk - Share price stability

Here's Why China Health Group Limited's (HKG:673) CEO Compensation Is The Least Of Shareholders' Concerns

Non-Executive Director recently bought HK$291k worth of stock

China Health Group Limited Announces Redesignation of Xing Yong from A Non- Executive Director to an Executive Director

Full year 2024 earnings released: HK$0.085 loss per share (vs HK$0.099 loss in FY 2023)

China Health Group Limited, Annual General Meeting, Sep 12, 2024

New minor risk - Shareholder dilution

Full year 2024 earnings released: HK$0.084 loss per share (vs HK$0.099 loss in FY 2023)

China Health Group Limited to Report Fiscal Year 2024 Results on Jun 27, 2024

First half 2024 earnings released: HK$0.032 loss per share (vs HK$0.066 loss in 1H 2023)

New major risk - Revenue and earnings growth

China Health Group Limited to Report First Half, 2024 Results on Nov 30, 2023

Shareholders Will Probably Not Have Any Issues With China Health Group Limited's (HKG:673) CEO Compensation

New minor risk - Shareholder dilution

China Health Group Limited, Annual General Meeting, Sep 18, 2023

Full year 2023 earnings released: HK$0.099 loss per share (vs HK$0.03 loss in FY 2022)

New minor risk - Insider selling

Full year 2023 earnings released: HK$0.099 loss per share (vs HK$0.03 loss in FY 2022)

China Health Group Limited to Report Fiscal Year 2023 Results on Jun 30, 2023

Executive Chairman recently bought HK$932k worth of stock

First half 2023 earnings released: HK$0.066 loss per share (vs HK$0.013 loss in 1H 2022)

We Think China Health Group (HKG:673) Has A Fair Chunk Of Debt

First half 2023 earnings released: HK$0.066 loss per share (vs HK$0.013 loss in 1H 2022)

China Health Group Limited Provides Earning Guidance for the Six Months Ended 30 September 2022

China Health Group Limited to Report First Half, 2023 Results on Nov 30, 2022

Less than half of directors are independent

We Discuss Why China Health Group Limited's (HKG:673) CEO May Deserve A Higher Pay Packet

China Health Group Limited, Annual General Meeting, Sep 30, 2022

Full year 2022 earnings released: HK$0.003 loss per share (vs HK$0.002 loss in FY 2021)

Full year 2022 earnings released

China Health Group Limited to Report Fiscal Year 2022 Results on Jun 30, 2022

China Health Group Limited announced that it expects to receive HKD 82 million in funding

Less than half of directors are independent

First half 2022 earnings: Revenues and EPS in line with analyst expectations

First half 2022 earnings: Revenues and EPS in line with analyst expectations

We Think Some Shareholders May Hesitate To Increase China Health Group Limited's (HKG:673) CEO Compensation

Full year 2021 earnings released: HK$0.002 loss per share (vs HK$0.009 loss in FY 2020)

No-Executive Director has left the company

China Health Group Limited Announces Board Changes

Did China Health Group Limited (HKG:673) Insiders Sell Shares?

First half 2021 earnings released: HK$0.001 loss per share

First half 2021 earnings released: HK$0.001 loss per share

China Health Group Limited to Report First Half, 2021 Results on Nov 30, 2020

Full year earnings released - HK$0.0089 loss per share

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin